Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers
CNW Group - Mon Jul 28, 6:00AM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
Lorus Therapeutics Reports Results for the Fourth Quarter and Full Year Ended May 31, 2014
CNW Group - Tue Jul 15, 3:46PM CDT
Lorus Therapeutics Inc. (TSX: LOR) today reported financial results for the year and three months ended May 31, 2014 and provided an overview of fiscal 2014 highlights and recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars.
Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing
PR Newswire - Tue Jul 15, 3:28PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the"Company"
Lorus Therapeutics To Host Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
CNW Group - Thu Jul 10, 6:00AM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced that the Company will release its fourth quarter and year end 2014 financial results on Tuesday, July 15, 2014 after the close of the market. The company intends to host a conference call on the same day at 5:00 p.m. EDT to discuss the financial results.
Lorus Therapeutics to Present at the 9th JMP Securities Healthcare Conference
CNW Group - Thu Jun 19, 6:00AM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will present at the 2014 9th JMP Securities Healthcare Conference on Wednesday, June 25, 2014, at 12:00 p.m. ET at the Westin New York Grand Central in New York City. Dr. Rice will provide a corporate overview of the Company's recent financing activities and strategic direction including plans to develop Lorus' lead clinical agent LOR-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
Lorus Therapeutics to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
PR Newswire - Mon Jun 16, 6:00AM CDT
Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 10:30 a.m. ET at the Toronto Board of Trade in Toronto. Dr. Rice will provide a corporate overview of the Company's strategic direction including plans to develop Lorus' lead clinical agent LOR-253 for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies.
Lorus Therapeutics Provides Update on Warrants
PR Newswire - Tue Jun 10, 6:30AM CDT
Lorus Therapeutics Inc. (TSX: LOR) (Lorus"
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Marketwire - Thu Mar 27, 4:01PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company"
IIROC Trade Resumption - LOR (all issues)
CNW Group - Thu Mar 27, 10:15AM CDT
Trading resumes in:
IIROC Trading Halt - LOR
CNW Group - Wed Mar 26, 2:38PM CDT
The following issues have been halted by IIROC:
Lorus Therapeutics Announces the Departure of Its President and Chief Operating Officer
Marketwire - Tue Mar 18, 7:24PM CDT
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company"